Mazdutide vs Semaglutide
Updated 6 sources
Key differences
- 1Semaglutide is GLP-1 only. Mazdutide adds glucagon activity aimed at energy use and liver fat.
- 2Innovent's DREAMS-3 phase 3 trial compares them head to head in Chinese adults with type 2 diabetes and obesity.
Side by side
Facts from each record, in the same words as their own pages.
| Mazdutide | Semaglutide | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
| Not reported |
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
6 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study2
- Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: rationale, design and baseline data of DREAMS-3Contemporary Clinical Trials (PubMed record) · checked Oct 24, 2026
- IBI362 (LY3305677) in Chinese adults with overweight or obesity: a multiple ascending dose phase 1b studyeClinicalMedicine (PMC) · checked Oct 24, 2026
Regulatory4
- Ozempic Prescribing Information (rev. 01/2025)FDA · checked Oct 23, 2026
- Wegovy injection and tablets label (SPL v19, Jun 30 2026)DailyMed · checked Oct 24, 2026
- Mazdutide: First ApprovalDrugs (PubMed record), via a reference work · checked Oct 24, 2026
- Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 DiabetesInnovent Biologics (via BioSpace), via a news report · checked Oct 24, 2026